We do not assume future debt refinancing or the rolling over of CP, regardless of the company's perceived credit strength or issuer credit rating. For instance, even for investment-grade issuers, we do not assume future debt maturities are refinanced with potential uncommitted capital raises. We could, however, consider a shorter time horizon.When an issuer has a shared revolving credit facility with a captive finance entity, for purposes of calculating the issuer's liquidity sources, we net outstanding commercial paper at the captive from the revolver's borrowing availability. In these cases, we generally use an estimate of peak CP borrowings at the captive to avoid potentially overstating sources available to the issuer over a 12- to 24-month period.
What is the prediction for NASDAQ:CLDX stock?
We do not assume future debt refinancing or the rolling over of CP, regardless of the company's perceived credit strength or issuer credit rating. For instance, even for investment-grade issuers, we do not assume future debt maturities are refinanced with potential uncommitted capital raises. We could, however, consider a shorter time horizon. We estimate CLDX Celldex Therapeutics stock forecast parameters by: Price with Paired T-Test because has further large bullet maturities next year and its reliance on alternative financing (7% Forecasted Return)NASDAQ:CLDX Stock Forecast (Buy or Sell) as of 15 Jun 2022 for (n+16 weeks)
Stock: CLDX Celldex TherapeuticsTime series to forecast n: 15 Jun 2022 for (n+16 weeks)
y axis:Potential Impact %
z axis:Color (yellow to green) Technical Analysis %
